Effect of warfarin and rivaroxaban in coronary endartherectomy
Phase 2
Recruiting
- Conditions
- Condition 1: Coronary arthry disease. Condition 2: .Atherosclerotic heart disease
- Registration Number
- IRCT20181124041746N1
- Lead Sponsor
- Kermanshah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Patients undergoing CABG and endarterectomy
Exclusion Criteria
Patients with prosthetic valve
ESRD patents
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms differentiate warfarin and rivaroxaban in coronary endarterectomy patients?
How does rivaroxaban compare to warfarin in post-operative outcomes for atherosclerotic heart disease patients?
Are there specific biomarkers that predict anticoagulant response in coronary artery disease patients undergoing endarterectomy?
What adverse events are associated with warfarin versus rivaroxaban in open heart surgery recovery?
How do newer anticoagulants like apixaban or dabigatran compare to rivaroxaban and warfarin in coronary endarterectomy management?